Previous close | 15.67 |
Open | 14.66 |
Bid | 14.50 |
Ask | 14.85 |
Strike | 125.00 |
Expiry date | 2025-01-17 |
Day's range | 14.66 - 14.80 |
Contract range | N/A |
Volume | |
Open interest | 1.2k |
ResMed stock jumped Thursday after an analyst suggested the growing popularity of weight-loss drugs could drive use of its medical devices.
Indian drugmaker Biocon, looking to grab a piece of the exploding weight-loss drug market as early as possible, is developing its own version of Novo Nordisk's wildly popular Wegovy and is prepared to conduct a clinical trial next year if needed, the CEO told Reuters. Wall Street has forecast the market for this new generation of obesity treatments reaching at least $100 billion by the end of the decade, and Biocon is taking steps to be a part of that windfall. "We're going to develop semaglutide for India even if it requires a clinical trial," Chief Executive Officer Siddharth Mittal said in an interview of the active ingredient in Wegovy and Ozempic.
Lilly is soon planning to ask global regulators to approve tirzepatide for sleep apnea treatment. Is Eli Lilly stock a buy?